TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Health Catalyst ( (HCAT) ).
On December 1, 2025, Health Catalyst appointed Matt Arens, CEO and Founder of its largest shareholder First Light Asset Management, to its Board of Directors, expanding the Board from eight to nine members. Arens, who brings extensive experience in capital markets and healthcare investment, waived compensation for his Board service except for expense reimbursement. Concurrently, Matthew Kolb announced he would not stand for re-election at the 2026 annual meeting, leading to a planned reduction of the Board back to eight members.
The most recent analyst rating on (HCAT) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Health Catalyst stock, see the HCAT Stock Forecast page.
Spark’s Take on HCAT Stock
According to Spark, TipRanks’ AI Analyst, HCAT is a Neutral.
Health Catalyst’s overall stock score is primarily impacted by its financial performance challenges, including consistent losses and profitability issues. Technical analysis suggests a bearish trend, and valuation concerns are heightened by a negative P/E ratio. Despite some positive earnings call highlights, the overall outlook remains cautious.
To see Spark’s full report on HCAT stock, click here.
More about Health Catalyst
Health Catalyst, Inc. is a leading provider of data and analytics technology and services for healthcare organizations. The company offers a cloud-based technology ecosystem, AI-enabled data and analytics solutions, and expert services to drive clinical, financial, and operational improvements across numerous patient records globally.
Average Trading Volume: 652,435
Technical Sentiment Signal: Sell
Current Market Cap: $205.8M
Find detailed analytics on HCAT stock on TipRanks’ Stock Analysis page.